Member Info for Lottohopes

I do agree that talking up and talking down the share price is irrelevant. The market understands the science and the context of the information presented better than most of us possibly can. But the results of other trials for which this company supplies cell therapy material is also a key factor. Novartis trials are ongoing on CAR T CELL therapy, and the company hopes to introduce this as treatment for Non Hodgkins Lymphoma, to US regulators in 2017. Estimated cost initially per patient: $450,000, which is a barrier to commercialisation. But if CART gives someone a lifeline , I doubt commercialisation can be prevented, and costs will drop with adoption. Novartis has set up its own manufacturing facilities in Morris Plains, in the US, but I don't think it will rely on anyone except OXB this side of the pond. Plus the lentivector method of introducing antigen expression is definitely OXBs baby, even if it's licensed out. Success in this area=greater demand for OXB product/s=£££ in royalties. And remember this is regardless of OXBs own product success: the combo of lentivector plus CART etc. And OXB has similar contracts with atleast three other BIG players: sanofi, GSK, Pfizer.....the odds are one of these will click and produce annual royalties soon. Every time a trial using OXB material progresses a step, it gets paid. Ex: Sanofi paid it £1 million on account of ocular disease trial going into human phase. Just my two pence, and of course i m biased as I m invested.

Just newbie questions: why is the funding being sought from the US, when it adds the exchange rate etc into the equation. And how will new money be raised? More share issues? Or further loan facilities?

I do think even if there is a general reversal of bull sentiment, in a contrarian sense investors may look for value in companies like OXB at that point too....I am biased as I m invested in this, and find gene therapy fascinating. Time will tell 😊

Short answer imho, yes. F215 Results due on 28th April which will presumably show company's cash position improving due to 2-3 world class sites, supplying IMPs to big companies like Novartis-with payment upfront and ongoing. The costs associated with setting up the new facilities (lab, staff training, certification etc) for these products was already factored into previous financial results ie interim 15 results, whilst the labs became functional in second half FY15. It's an exciting point, as the company's commercial arm will start improving funding for the rest, there may be reduction of the utilised portion of the loan facility...how much revenue the commercial arm is producing will decide the ceiling of sp, atleast short term....there's the (more) exciting prospect of some study results being referred to as well.......all just my humble opinion from reading info on the net.

I can imagine how disheartening it must be, to hold a paper loss and wait patiently. I reckon 28th April will turn the tide. GLA

I really like this company's product line. I agree-no obvious reason for falling price for what looks like a great company.....I wonder if the smart money knows of imminent share issue, as RNS of Feb 2016 which announced 8.1 million issue, also mentions that further equity finance will need to raised in 2016 to cover costs? Just sheer speculation on my part